Literature DB >> 17691932

Molecular mechanisms of diabetic nephropathy and its therapeutic intervention.

Sho-ichi Yamagishi1, Kei Fukami, Seiji Ueda, Seiya Okuda.   

Abstract

Diabetic nephropathy is a leading cause of end-stage renal failure, which could account for disabilities and high mortality rates in patients with diabetes. Diabetic nephropathy seems to occur as a result of an interaction between metabolic and hemodynamic factors, which activate common pathways that lead to renal damage. Recent large landmark clinical studies have shown that intensive glucose control reduces the risk of the development and progression of diabetic nephropathy, and the blockade renin-angiotensin system (RAS) is also an important target for both metabolic and hemodynamic derangements in diabetic nephropathy. However, diabetic nephropathy remains the leading cause of end-stage renal failure in developed countries. Therefore, to develop novel therapeutic strategies that specifically target diabetic nephropathy may be helpful for most patients with diabetes. High glucose, via various mechanisms such as increased production of oxidative stress and advanced glycation end products (AGEs), and activation of the RAS and protein kinase C (PKC), elicits vascular inflammation and alters gene expression of growth factors and cytokines, thereby it might be involved in the development and progression of diabetic nephropathy. This article summarizes the molecular mechanisms of diabetic nephropathy and the potential therapeutic interventions that may prevent this devastating disorder even in the presence of hyperglycemia, control of which is often difficult with current therapeutic options.

Entities:  

Mesh:

Year:  2007        PMID: 17691932     DOI: 10.2174/138945007781386884

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  38 in total

1.  Evaluation of genetic association and expression reduction of TRPC1 in the development of diabetic nephropathy.

Authors:  Dongying Zhang; Barry I Freedman; Milan Flekac; Elisabete Santos; Pamela J Hicks; Donald W Bowden; Suad Efendic; Kerstin Brismar; Harvest F Gu
Journal:  Am J Nephrol       Date:  2008-09-19       Impact factor: 3.754

2.  Association between the T869C polymorphism of transforming growth factor-beta 1 and diabetic nephropathy: a meta-analysis.

Authors:  Hongxia Jia; Lili Yu; Bin Gao; Qiuhe Ji
Journal:  Endocrine       Date:  2011-07-02       Impact factor: 3.633

Review 3.  A novel improved therapy strategy for diabetic nephropathy: targeting AGEs.

Authors:  Xuemei Zhou; Bochu Wang; Liancai Zhu; Shilei Hao
Journal:  Organogenesis       Date:  2012-01-01       Impact factor: 2.500

4.  Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease.

Authors:  Murthy N Darisipudi; Onkar P Kulkarni; Sufyan G Sayyed; Mi Ryu; Adriana Migliorini; Costanza Sagrinati; Eliana Parente; Axel Vater; Dirk Eulberg; Sven Klussmann; Paola Romagnani; Hans-Joachim Anders
Journal:  Am J Pathol       Date:  2011-04-30       Impact factor: 4.307

Review 5.  Steroid resistance in leukemia.

Authors:  Darshan S Shah; Raj Kumar
Journal:  World J Exp Med       Date:  2013-05-20

Review 6.  Advanced glycation end products, oxidative stress and diabetic nephropathy.

Authors:  Sho-Ichi Yamagishi; Takanori Matsui
Journal:  Oxid Med Cell Longev       Date:  2010 Mar-Apr       Impact factor: 6.543

Review 7.  Diabetes and its comorbidities--where East meets West.

Authors:  Alice P S Kong; Gang Xu; Nicola Brown; Wing-Yee So; Ronald C W Ma; Juliana C N Chan
Journal:  Nat Rev Endocrinol       Date:  2013-05-28       Impact factor: 43.330

8.  Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes.

Authors:  S G Sayyed; H Hägele; O P Kulkarni; K Endlich; S Segerer; D Eulberg; S Klussmann; H-J Anders
Journal:  Diabetologia       Date:  2009-08-26       Impact factor: 10.122

9.  Diabetic nephropathy: Treatment with phosphodiesterase type 5 inhibitors.

Authors:  Cecil Stanley Thompson
Journal:  World J Diabetes       Date:  2013-08-15

10.  Diabetic nephropathy.

Authors:  Themis Zelmanovitz; Fernando Gerchman; Amely Ps Balthazar; Fúlvio Cs Thomazelli; Jorge D Matos; Luís H Canani
Journal:  Diabetol Metab Syndr       Date:  2009-09-21       Impact factor: 3.320

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.